Clinical Utility of Dual‐Time 68 Ga‐Pentixafor PET/CT in Diagnosing and Subtyping Primary Aldosteronism
Clinical Endocrinology · 2025-05 · 102 (5) · 499-509
DOI: 10.1111/cen.15204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 26.01.2025. Verfasst von Rui Zuo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Hyperaldosteronism, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: This work was supported by the first affiliated hospital of Chongqing Medical University (Grant 030102050401CYYY-DSTDXM-202420)..
Abstract (Originalsprache)
Objectives
This study aimed to compare the clinical efficacy of dual‐time 68 Ga‐pentixafor PET/CT with adrenal vein sampling (AVS) in PA lateralization. Methods and Methods We retrospectively analysed 161 patients with PA. We assessed the diagnostic performance of dual‐time 68 Ga‐pentixafor PET/CT in diagnosing unilateral primary aldosteronism (UPA) and aldosterone‐producing adenoma (APA). We also explored the relationship between 68 Ga‐pentixafor PET/CT findings, postoperative outcomes, and the presence of the KCNJ5 gene mutation.
Results
The diagnostic accuracy of 68 Ga‐pentixafor PET at 10 and 40 min for UPA (75.2% and 76.4%, respectively) surpassed that of CT (55.3%, p < 0.01). The optimal cutoff for diagnosing APA was 10 min lesion‐to‐normal adrenal ratio = 1.95, yielding an AUC of 91.9%, with sensitivity, specificity, and accuracy of 76.0%, 91.3%, and 83.3%, respectively. This high diagnostic efficacy extended to subgroups with nodules ≥ 1 or < 1 cm, and the largest AUC of 68 Ga‐pentixafor PET/CT for diagnosis APA with lesions ≥ 1 and < 1 cm is 88.2% and 97.0%, respectively. The lateralization results provided by 68 Ga‐pentixafor PET/CT corroborated the surgical treatment decision in 92.0% of PA patients, and more than 95% achieved clinical and/or biochemical cure or improvement. The PET positive rate of KCNJ5 mutation was higher than that of KCNJ5 wild‐type, with optimal diagnostic efficacy at 40 min lesion‐to‐liver ratio = 4.79 (AUC 81.3%, sensitivity 90.0%, specificity 66.7%).
Conclusion
Dual‐time 68 Ga‐pentixafor PET/CT exhibits robust diagnostic efficacy in PA lateralization. Furthermore, 68 Ga‐pentixafor PET/CT holds promise as an imaging marker for predicting the presence of the KCNJ5 mutation in PA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Förderung
- This work was supported by the first affiliated hospital of Chongqing Medical University (Grant 030102050401CYYY-DSTDXM-202420).
Zitieren
APA
Zuo, R., Liu, S., Ren, X., Li, W., Xia, Z., Xu, L., & Pang, H. (2025). Clinical Utility of Dual‐Time 68 Ga‐Pentixafor PET/CT in Diagnosing and Subtyping Primary Aldosteronism. Clinical Endocrinology, 102(5), 499-509. https://doi.org/10.1111/cen.15204
Vancouver
Zuo R, Liu S, Ren X, Li W, Xia Z, Xu L, et al. Clinical Utility of Dual‐Time 68 Ga‐Pentixafor PET/CT in Diagnosing and Subtyping Primary Aldosteronism. Clinical Endocrinology. 2025;102(5):499-509. doi:10.1111/cen.15204
BibTeX
@article{Zuo2025,
author = {Zuo, Rui and Liu, Shuang and Ren, Xinyi and Li, Wenbo and Xia, Zhu and Xu, Lu and Pang, Hua},
title = {Clinical Utility of Dual‐Time 68 Ga‐Pentixafor PET/CT in Diagnosing and Subtyping Primary Aldosteronism},
journal = {Clinical Endocrinology},
year = {2025},
volume = {102},
number = {5},
pages = {499--509},
doi = {10.1111/cen.15204}
}
EUVIMED